Replies to post #225882 on Biotech Values

[DewDiligence]

NKTR—...more likely the lower RR is not due to this and now they have both a drug w low or no activity and a CMC issue to boot...

Agreed:

It could be a combination of both, but I put more credence on regression to the mean.

— Roy Friedman (@DewDiligence) August 9, 2019

.